Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of NTM-1634 in Healthy Adults
NCT03046550Phase 1Completed
- Sponsor
- Resilience Government Services
- Start
- Mar 2017
- Primary completion
- Oct 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NTM-1634 in botulism (3 cohorts), sponsored by Resilience Government Services. Primary endpoints: Serious Adverse Events at 121 days, Adverse Events at 57 days and 4 more. Started Mar 2017; status: completed.
02
Drugs
NTM-1634
03
Conditions
botulism
Beyond the preview
Go deeper on NCT03046550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03046550.